Timolol recall

Article

Bottles of timolol ophthalmic solution 0.25% and 0.5% (Sandoz Canada Inc.) have been recalled in Canada because of an increased risk of adverse events.

Bottles of timolol ophthalmic solution 0.25% and 0.5% (Sandoz Canada Inc.) have been recalled in Canada because of an increased risk of adverse events. Health Canada issued a warning after it emerged that some bottles of the intraocular pressure (IOP) lowering drops contained a higher-than-indicated level of active ingredient timolol maleate.

The excess timolol maleate could induce adverse events including red eye, irritation, blepharitis, keratitis, ptosis, and diplopia. Other non-ocular potential adverse events include dizziness, headache, bradycardia, hypotension, shortness of breath, difficulty breathing and cardiac failure.

Patients currently using the products have been advised to discontinue treatment immediately and return the bottle to their pharmacist. Sandoz has recalled the products; Health Canada will continue to monitor the situation. Currently, no adverse events relating to the mislabelled products have been noted.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.